A Two-phase, Multicenter, Open Phase I Study of BEBT-607 Tablets in The Treatment of Advanced or Metastatic Solid Tumors With KRAS G12C Mutation
Latest Information Update: 21 Aug 2026
At a glance
- Drugs BEBT-607 (Primary)
- Indications Colorectal cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors BeBetter Med
Most Recent Events
- 18 Aug 2026 Status changed from recruiting to completed.
- 14 Nov 2023 New trial record